Every material Form 8-K Editas Medicine, Inc. has filed with the SEC since May 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Editas Medicine reported third quarter 2026 results, with a net loss attributable to common stockholders of $23.4 million, or $0.15 per share, down from $25.1 million, or $0.28 per share, a year earlier. Collaboration revenue rose to $10.4 million from $7.5 million, driven mainly by partner milestone revenue, while research and development and general and administrative expenses also increased. The company said its cash runway extends into the second half of 2028.
Net loss attributable to common stockholders was $23.4 million, or $0.15 per share, for the three months ended September 30, 2026, versus $25.1 million, or $0.28 per share, a year earlier.
Collaboration and other research and development revenues increased to $10.4 million from $7.5 million, mainly from milestones achieved by a strategic partner.
Cash, cash equivalents, and marketable securities were $190.2 million as of September 30, 2026, up from $146.6 million at December 31, 2025, and are expected to fund operations into the second half of 2028.
Editas received Australian ethics and regulatory approval to start the Phase 1/2 Strive study of EDIT-401, with initial safety and tolerability data expected in the first quarter of 2027.
Editas Medicine said it received approval to start the Phase 1/2 Strive trial of its experimental gene editing medicine EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia, and submitted the trial for review in New Zealand. The filing states that the company expects to report initial safety and tolerability data in the first quarter of 2027, with topline safety and efficacy data later in 2027, so the program is still at an early clinical stage with no financial results attached.
Trial received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration
Trial has been submitted for review in New Zealand; patients in both countries would be eligible to enroll if approved there
Initial safety and tolerability data expected in the first quarter of 2027
New preclinical data on LDL-C reduction will be presented at the AHA Scientific Sessions on November 8, 2026
Editas Medicine reported a second-quarter 2026 net loss of $18.2 million, or $0.15 per share, down from $53.2 million, or $0.63 per share, a year earlier, while collaboration revenue rose to $11.9 million from $3.6 million. The company said its cash runway now extends into the second half of 2028 following a May public offering, and it added Patrick Ellinor, M.D., Ph.D. to its board effective August 6, 2026.
Net loss of $18.2 million, or $0.15 per share, for the quarter ended June 30, 2026, versus $53.2 million, or $0.63 per share, a year earlier.
Collaboration and other R&D revenues of $11.9 million, up from $3.6 million, mainly from recognition of deferred revenue tied to the BMS collaboration.
Cash and cash equivalents of $211.6 million at June 30, 2026, following a May public offering with $125.0 million in gross proceeds.
Elliott Levy, M.D., resigned from the board effective August 4, 2026; Patrick Ellinor, M.D., Ph.D. was appointed an independent director effective August 6, 2026.
Editas Medicine agreed to sell 55,555,556 shares of common stock, each paired with a common stock warrant, at a combined price of $2.25, with net proceeds estimated at $117.0 million. The company said the proceeds, together with its cash as of March 31, 2026, should fund operations into the second half of 2028, and the warrants could add about $192.5 million if fully exercised for cash, which would also dilute existing holders.
Gross offering size of about $125.0 million before underwriting discounts and offering expenses, with closing expected on or about May 27, 2026
Cash runway extended to the second half of 2028, based on current plans and assumptions the company says may prove wrong
Warrants have a $3.50 per share exercise price and expire on the earlier of 30 days after Phase 1 EDIT-401 data showing at least three patients with greater than 80% LDL-cholesterol reduction, or three years from issuance
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Editas Medicine, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →